Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

CAPRA + Epstein prostate risk panel

A neutral two-component orchestration panel using the verified original UCSF-CAPRA and historical Johns Hopkins Epstein production implementations.

Evidence-based context for fast calculator use

Purpose:
Display two source-specific results in parallel without creating a combined score or recommendation.
Population:
Component-specific pretreatment prostate cancer contexts; each child independently enforces its own source scope.
Factors:
CAPRA age/PSA/grade/stage/core burden, Epstein cT1c/PSA density/grade/core burden/context
Reference:
Cooperberg et al. J Urol. 2005; Carter et al. J Urol. 1997 following Epstein et al. JAMA 1994.
HomeCAPRA + Epstein Prostate Risk Panel
Pin your most used calculators here by clicking the star in the dropdown.

CAPRA + Epstein Prostate Risk Panel

years
ng/mL
cc
%

Clinical Context & Background

This panel runs two separately verified, source-specific prostate tools through their shared production implementations:
Original 2005 UCSF-CAPRA
A preoperative 0-10 score associated with postoperative biochemical recurrence risk in the original radical-prostatectomy cohort. Its age, PSA, biopsy grade, clinical stage, and unrounded positive-core percentage rules are preserved exactly.
Johns Hopkins Epstein T1c pretreatment criteria
A historical interpretation of the four 1997 operational thresholds following the 1994 cT1c derivation. Its endpoint is a historical prostatectomy pathology classification, not modern active-surveillance eligibility.
The two outputs answer different questions. This panel summarizes component availability only. It does not merge scores, create a consensus category, estimate treatment benefit, or recommend surveillance or treatment.
The unsupported embedded NCCN v4.2024 branch has been removed. This panel does not implement, reproduce, infer, or validate NCCN prostate risk-group logic.
Formula Logic
Orchestration only: project the relevant raw fields into the verified CAPRA and Epstein production implementations, preserve each child result and trace, and summarize availability without combining endpoints.

Reference Data

ComponentSource-specific outputInterpretive boundary
UCSF-CAPRA: Low RiskScore 0-2Original preoperative recurrence-risk association
UCSF-CAPRA: Intermediate RiskScore 3-5Original preoperative recurrence-risk association
UCSF-CAPRA: High RiskScore 6-10Original preoperative recurrence-risk association
Epstein: Criteria metAll exact historical thresholds passHistorical prostatectomy pathology endpoint only
Epstein: Criteria not metOne or more exact thresholds failNo diagnosis, surveillance, or treatment inference

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use when the raw pretreatment inputs required by one or both source-specific components are available.
  • Interpret each component under its own source scope.

How To Interpret

  • Read the CAPRA and Epstein cards separately.
  • An unavailable or out-of-scope child does not alter the other child.

What To Do Next

  • Use the actual source-specific result with contemporary specialist assessment.
  • Do not infer a combined category or treatment plan from panel availability.

Limitations

  • CAPRA and Epstein have different historical endpoints and populations.
  • The panel does not implement NCCN risk groups or replace current guideline assessment.

Validated Population

Software orchestration parity is verified against the separately source-locked CAPRA and Epstein implementations.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed production cases passed through visible controls across the CAPRA age threshold and the exact Epstein PSA-density and maximum-core-involvement boundaries.
    • Observed independent results matched exactly: CAPRA 1 / Low with Epstein criteria met, CAPRA 0 / Low with criteria met, and CAPRA 1 / Low with criteria not met at PSA density 0.15 and 50% involvement.
    • The published panel presents CAPRA and Epstein separately with no agreement/discordance synthesis, combined score, stale controls, literal undefined/null values, or visible error boundary.
    Download latest production check (Excel)

    Case-level production evidence is retained in validation/browser-revalidation/panel-prostate-risk-production-closure-2026-08-03.json.

  2. : Local independent-component summary remediation

    • Three visible-control cases covered the baseline, the CAPRA age-49 transition, and the exact Epstein PSA-density/50-percent-involvement failure boundaries.
    • The concise receipt now labels the second column `Independent result` and keeps CAPRA recurrence-risk association separate from the historical Epstein pathology endpoint.
    • All component results and exact equality behavior matched; 976/976 assertions passed and the browser console was clean.

    Case evidence is retained in validation/browser-revalidation/panel-prostate-risk-local-remediation-2026-08-03.json.

  3. : Production browser revalidation — UI finding retained

    • Three source-backed cases matched independent CAPRA and Epstein results at CAPRA 1, the age-49 CAPRA transition, and both exact Epstein exclusion boundaries.
    • Production still labels the panel summary `RESULT / AGREEMENT` and instructs users to `review agreement or discordance clinically`, outside the neutral parallel-results contract.
    • Overall production status remains failed-ui-safety until that residual synthesis wording is removed and revalidated; no browser-console error was observed.

    Case-level evidence and reproduction are retained in validation/browser-revalidation/panel-prostate-risk-2026-08-03.json.

  4. : Local browser remediation verified; production retest pending

    • Ten source-backed cases passed through visible controls on the corrected local route across 12 submissions, including one exact-wording boundary reproduction.
    • CAPRA and historical Epstein outputs remained separate across score thresholds, PSA-density boundaries, source-context inapplicability, warnings, and reset/repeat behavior.
    • The old Unified Panel Results heading, Combined assessment subtitle, unified-result agreement instruction, and literal undefined output did not appear. The original production findings remain open until deployment and public revalidation.

    Case-level local remediation evidence is retained in validation/browser-production/panel-prostate-risk.local-remediation.json.

  5. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 0/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-ui-safety-and-console. critical: Every rendered case was headed `Unified Panel Results`, described as a `Combined assessment from multiple tools`, and instructed users to compare `agreement and discordance alongside the unified panel result`. | medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/panel-prostate-risk.json.

  6. : Exact input guidance for unavailable components

    • CAPRA and Epstein skipped, incomplete, and invalid results now use "Please review" and identify the exact visible entries in parentheses.
    • No CAPRA score mapping, Epstein threshold, projection, or component-isolation behavior changed.

    All 976 existing panel assertions pass; current report remains applicable.

  7. : Input workflow simplified and revalidated

    • Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
    • Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
    • Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.

  8. : Browser serialization and partial-component verification

    • Normalized finite browser number-control values into the exact thirteen-string model envelope while preserving zero and keeping undefined, null, and blank values absent.
    • Verified all-blank and shared-only submissions skip both scores, a complete CAPRA-only or Epstein-only section calculates independently, and a partial component is invalid without suppressing or altering its complete sibling.
    • Passed 976/976 deterministic assertions without changing the published CAPRA or Epstein formulas, thresholds, result serializers, or source-specific interpretations.

  9. : Epstein child projection verified

    • The panel calculates PSA density from raw PSA and volume at full precision and calls the canonical source-versioned Epstein engine.
    • Non-cT1c disease, post-treatment timing, noncomparable biopsy sampling, and discordant PSA-density context suppress only Epstein. At that time, complete panel orchestration remained in review.

    See the Epstein calculator's verification history for its supporting report.

  10. : Source reconciliation / unsupported NCCN branch removed

    • Removed the unsourceable embedded NCCN v4.2024 grouping branch, treatment directives, and NCCN-derived parent classification while preserving the permanent panel route.
    • The current panel is explicitly limited to the separately source-locked original UCSF-CAPRA and historical Johns Hopkins Epstein T1c components.

  11. : Full panel parity validation

    • Passed 960 deterministic assertions covering exact envelope rejection, CAPRA and Epstein parity, full-precision boundaries, malformed and invalid fixtures, sibling isolation, no cross-component leakage, neutral availability-only synthesis, trace integrity, linked content, report mirrors, registry and ledger.
    • This is software implementation verification of panel orchestration, not prospective or independent clinical validation of either source model.

  12. : CAPRA component verified

    • 128/128 valid standalone-to-panel CAPRA projections passed, including full-precision positive-core percentage, PSA equality, fewer-than-six-core warnings, and extended-stage warnings.
    • At that time, Epstein and complete panel orchestration remained in review; the former embedded NCCN branch was outside this component verification and has since been removed.

    See the CAPRA calculator's verification history for its supporting report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Myeloma R2-ISS and IMWG Frailty PanelFebrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

Does this panel calculate NCCN prostate risk groups?

No. The unsupported embedded NCCN branch was removed. The panel contains only the source-locked CAPRA and Epstein components.

Are CAPRA and Epstein results combined?

No. They have different endpoints and remain separate parallel results.

Does meeting the Epstein criteria recommend active surveillance?

No. The result is a historical pathology-endpoint interpretation, not a contemporary surveillance recommendation.

Evidence-based oncology decision support. Verify with clinical guidelines.